Oruka Therapeutics, Inc. Stock Analysis & AI Score
Oruka Therapeutics, Inc. (ORKA) has an ST Score of 65.5 (B), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $144.56 price target (+69.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Oruka Therapeutics, Inc. (ORKA) has an ST Score of 65.5 (B), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $144.56 price target (+69.1% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthF
All factor grades
- Financial StrengthA+
- SentimentA+
- ProfitabilityA
- ValuationA-
- MomentumA-
- ForecastB+
- GrowthF
- Piotroski2/9
Contact
ORKA stock: frequently asked questions
What is ORKA's ST Score?
Oruka Therapeutics, Inc. (ORKA) has an ST Score of 65.5 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ORKA a buy, hold, or sell?
Analysts rate ORKA a Buy, with a price target of $144.56 (+69.1% vs the current price). Our ST Score grades it B (65.5/100). The ST Score is a data-driven signal, not a recommendation.
What are ORKA's factor grades?
Valuation A-, Profitability A, Financial Strength A+, Momentum A-, Growth F, Forecast B+, Sentiment A+.
What is ORKA's valuation grade?
Oruka Therapeutics, Inc. (ORKA) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ORKA's growth grade?
Oruka Therapeutics, Inc. (ORKA) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ORKA's profitability grade?
Oruka Therapeutics, Inc. (ORKA) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ORKA's financial strength grade?
Oruka Therapeutics, Inc. (ORKA) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ORKA?
The average analyst price target for Oruka Therapeutics, Inc. (ORKA) is $144.56 from 9 analysts, which is +69.1% versus the recent price of $85.49.
What is ORKA's Piotroski score?
Oruka Therapeutics, Inc. (ORKA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.